Successful medical management of severe neonatal Cushing syndrome with metyrapone, guided by mass spectrometry monitoring

A. Poidvin (1), C. Storey-London (1,4), L. Martinerie (1,4), J. Léger (1,4), K. Braun (2), N. Lahlou (3), J.C. Carel (1,4)

(1) Robert Debré Hospital, Paediatric Endocrinology and Diabetology Assistance Publique – Hôpitaux de Paris, Paris, France
(2) Amiens University Hospital, Pediatrics Unit, Endocrinology, CHU Amiens Sud, Amiens, France
(3) Cochin University Hospital, Specialized Homonology and Metablosim Laboratory, Assistance Publique – Hôpitaux de Paris, Paris, France
(4) University Paris Diderot, Sorbonne Paris Cité, Paris, France

Background

Neonatal Cushing syndrome is a rare and severe condition, mostly associated with the McCune-Albright (MCA) syndrome. Management options include medical treatment (with ketoconazole or metyrapone resulting in 11-beta-hydroxylase blockade) and radical treatment with bilateral adrenalectomy. Spontaneous regression in late infancy has been reported. We report on the outcome of a 14 month-old girl with severe neonatal Cushing syndrome on long-term treatment with metyrapone.

Clinical presentation

- Girl born with severe growth restriction (-4DS for height and weight)
- Neonatal hyperglycaemia requiring insulin treatment during 1 month
- At the age of 2 months:
  - growth arrest
  - clinical Cushingoid features
  - elevated circadian cortisol > 1000 nmol/L not suppressible by dexamethasone and undetectable ACTH levels.
  - Severe ACTH independent Cushing syndrome

Complications:
- Hypertension requiring 3 medications
- Hypotonia
- Immune depression resulting in Pneumocystis infection.
No other features of the McCune Albright syndrome

Therapeutic challenge

2 options:
- Radical treatment = Bilateral adrenalectomy, but irreversible
- Medical treatment with metyrapone:
  - 118 hydroxylase blockade
We chose the metyrapone, administered by nasogastric tubing, initiated at the dose of 80 mg every 6 hours.

Evolution

At the age of 18 months, hypercorticism was controlled with catch-up growth, disappearance of Cushingoid features, normal blood pressure and no clinical hyperandrogenism. Adrenal imaging showed persistently enlarged adrenals.

Diagnostic challenge

- Search for activating mutation of the GNAS gene in PBMC DNA: negative
- Sequencing of several genes involved in adrenal function (MC2R, ARMC5, PRKAR1A): normal
- But at 18 months:
  - signs of estrogenic impregnation without vaginal bleeding
  - ovarian cyst of 3 cm and stimulated uterus
  - McCune Albright syndrome

Conclusions

Long-term treatment of severe neonatal Cushing syndrome with metyrapone is efficient, well tolerated and can avoid bilateral adrenalectomy in transient cases. Mass spectrometry (UPLC-MSMS) for monitoring steroid changes is needed. This ultra specific method avoids overestimation of actual levels related to crossreactions between steroids.

References


The authors have no interest to disclose